AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly report

AbbVie has reported new quarterly figures while investors track how rising immunology drugs like Skyrizi and Rinvoq offset declining Humira sales. What the latest numbers reveal about the pharma group’s transition story.

AbbVie is in the middle of a multi?year transition as blockbuster drug Humira loses exclusivity, while newer immunology therapies Skyrizi and Rinvoq take over as growth drivers. The most recent quarterly results highlighted both the pressure from biosimilar competition and the strong uptake of the newer portfolio, according to AbbVie’s earnings release published in early May 2024 and subsequent updates referenced by major business media such as Reuters as of 05/03/2024.

For the first quarter of 2024, AbbVie reported worldwide net revenues of around 12.3 billion USD, with continued year?over?year declines in Humira offset by significant growth in Skyrizi and Rinvoq sales, based on figures in the company’s Q1 2024 report released on May 3, 2024 and summarized by AbbVie Investor Relations as of 05/03/2024. Management reiterated its focus on immunology, oncology and neuroscience as core long?term pillars and provided updated guidance for full?year adjusted earnings per share, underlining the importance of execution in the US market.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AbbVie Inc.
• Sector/industry: Pharmaceuticals, biotechnology
• Headquarters/country: North Chicago, United States
• Core markets: United States, Europe and international biopharma markets
• Key revenue drivers: Immunology, oncology, neuroscience and aesthetics therapies
• Home exchange/listing venue: New York Stock Exchange (ticker: ABBV)
• Trading currency: US dollar (USD)

AbbVie: core business model

AbbVie was created in 2013 as a spin?off from Abbott Laboratories and has since developed into one of the largest research?based biopharmaceutical groups globally. The company’s strategy centers on discovering, developing and commercializing advanced therapies for chronic illnesses, with a particular concentration on immunology, oncology, neuroscience, eye care and aesthetics. This focus positions AbbVie as a key player in high?value therapeutic categories where unmet medical need and pricing power can be significant, especially in the US market.

For many years, Humira was the centerpiece of AbbVie’s business model. The anti?TNF therapy, used to treat conditions such as rheumatoid arthritis and Crohn’s disease, generated tens of billions of dollars in cumulative sales and financed a broad pipeline. However, biosimilar competition began to erode Humira’s market share in Europe several years ago and reached the US market in 2023, putting pressure on AbbVie’s revenue and margin profile. The company anticipated this shift and invested heavily into next?generation immunology assets such as Skyrizi and Rinvoq to sustain growth as Humira declines.

Beyond immunology, AbbVie’s business model includes oncology therapies, where cancer treatments like Imbruvica and Venclexta provide targeted options for hematologic malignancies. While Imbruvica has also faced competitive headwinds and changing treatment paradigms, AbbVie continues to invest in combination regimens and next?generation assets. The company’s neuroscience portfolio includes treatments for psychiatric and neurological conditions, reflecting management’s view that these areas represent long?term opportunities as populations age and diagnosis rates improve.

Another pillar of AbbVie’s business model is its aesthetics franchise, led by Botox Cosmetic and other medical aesthetic products. This portfolio emerged from the 2020 acquisition of Allergan, a transaction that significantly broadened AbbVie’s revenue base and reduced dependence on any single product. The aesthetics business is more consumer?driven than traditional pharmaceuticals and can be sensitive to macroeconomic cycles, yet it offers attractive margins and brand recognition that complement AbbVie’s more traditional prescription drug lines.

AbbVie’s revenue model is heavily influenced by the US healthcare system, where pricing levels and reimbursement frameworks typically support higher margins than many international markets. As a result, US price dynamics, regulatory developments around drug costs and Medicare negotiations are closely watched by investors. AbbVie’s ability to navigate these policy debates while defending its intellectual property and optimizing its portfolio is central to its long?term value creation strategy in the eyes of market participants.

Main revenue and product drivers for AbbVie

Humira remains a material contributor to AbbVie’s revenues, but its share has fallen markedly as biosimilar alternatives gain traction. The Q1 2024 earnings release indicated another significant year?over?year decline in Humira sales, particularly in the United States, as payers and pharmacy benefit managers increasingly promote lower?priced competitors, according to data summarized by Reuters as of 05/03/2024. This erosion was widely anticipated by the market and is part of the reason AbbVie has guided investors toward a revenue mix in which newer drugs carry the growth mantle.

Skyrizi, a treatment for plaque psoriasis, psoriatic arthritis and Crohn’s disease, has emerged as one of the most important growth drivers in AbbVie’s portfolio. In the first quarter of 2024, Skyrizi delivered strong double?digit sales growth versus the prior?year period, reflecting continued market share gains and new indications, as outlined in the Q1 2024 report released on May 3, 2024 by AbbVie Investor Relations as of 05/03/2024. Management has highlighted Skyrizi as a cornerstone of its post?Humira strategy, noting the drug’s favorable efficacy profile and potential for additional label expansions.

Rinvoq, a JAK inhibitor indicated for rheumatoid arthritis, atopic dermatitis and other inflammatory conditions, is another critical growth engine. Sales in the first quarter of 2024 increased strongly compared with the same period a year earlier, supported by wider adoption in rheumatology and dermatology. Despite class?wide safety discussions around JAK inhibitors, AbbVie has emphasized Rinvoq’s clinical data and risk?benefit profile, and regulatory approvals in multiple geographies have underpinned its uptake. Rinvoq’s performance is monitored closely because it complements Skyrizi in building a diversified immunology franchise.

In oncology, AbbVie’s revenue base is more mixed. Imbruvica, developed in partnership with Johnson & Johnson, has encountered competitive pressure from newer BTK inhibitors and changing treatment guidelines. This dynamic has weighed on oncology growth, yet drugs like Venclexta have helped partially offset the impact. In addition, AbbVie continues to invest in early? and mid?stage oncology assets, including antibody?drug conjugates and targeted small molecules, to reposition its cancer portfolio for the next decade.

The aesthetics segment, anchored by Botox and Juvéderm, contributes a meaningful share of AbbVie’s total revenues and offers a different growth profile than prescription drugs. Demand for aesthetic procedures is influenced by consumer confidence and discretionary spending, which are closely tied to the health of the US economy. During periods of macroeconomic resilience, the segment can post robust growth, whereas downturns may dampen volumes. AbbVie’s broad geographic footprint in aesthetics, combined with strong brand recognition, allows it to maintain a significant presence even as competition intensifies.

Looking beyond individual products, AbbVie’s pipeline is a crucial component of its revenue outlook. The company invests billions of dollars annually in research and development, with a particular emphasis on immunology, oncology and neuroscience programs. Investors pay attention to clinical trial milestones, regulatory submissions and approval decisions from authorities such as the US Food and Drug Administration, as these events can rapidly alter expectations for AbbVie’s long?term revenue and earnings trajectory.

Industry trends and competitive position

AbbVie operates in a highly competitive global biopharmaceutical industry where innovation cycles, patent cliffs and regulatory decisions can rapidly shift market share. In immunology, competitors include companies such as Johnson & Johnson, Novartis and Eli Lilly, each offering or developing therapies for autoimmune and inflammatory diseases. The race to develop more targeted, efficacious and convenient treatments is intense, and differentiation often hinges on clinical data, safety profiles and administration convenience, all of which are closely scrutinized by physicians and payers in the US and abroad.

Pricing dynamics are another key industry trend. Policymakers in the United States have increasingly focused on lowering prescription drug costs, and legislative initiatives such as Medicare price negotiation mechanisms could have long?term implications for companies with high exposure to US government?funded programs. AbbVie’s portfolio includes products that are likely to be affected by such policies over time, which is one reason investors carefully follow the company’s commentary on pricing, access and contracting strategies during earnings calls and industry conferences, as covered by outlets like Bloomberg as of 05/04/2024.

The acquisition of Allergan in 2020 gave AbbVie a larger footprint across therapeutic areas and diversified its revenue streams. This strategic move positioned AbbVie more firmly against large peers with broad portfolios, including Pfizer and Merck, and created cross?selling opportunities across neurology, ophthalmology and aesthetics. The integration of Allergan also brought cost synergies and operational efficiencies, which management has referenced in recent financial communications, though such benefits need to be weighed against the higher debt load and ongoing investments required to keep the combined pipeline competitive.

From a research and development standpoint, AbbVie aims to balance internal discovery efforts with external collaborations and licensing deals. Partnerships with smaller biotech firms and academic institutions are a common industry practice that allows larger companies to access innovative technologies and niche expertise. AbbVie’s willingness to engage in such collaborations, while also advancing its in?house programs, is an important factor in maintaining a robust pipeline that can replenish revenues lost to patent expirations and competition.

Why AbbVie matters for US investors

AbbVie is listed on the New York Stock Exchange under the ticker ABBV, making it readily accessible for US retail investors through standard brokerage accounts and retirement plans. As a large?capitalization biopharmaceutical company, AbbVie is included in major equity indices, meaning that it is also a component of many index funds and exchange?traded funds held by US savers. Fluctuations in AbbVie’s share price can therefore influence the performance of diversified portfolios even for investors who did not select the stock directly.

The company’s significant exposure to the US healthcare system means that domestic policy changes around drug pricing, reimbursement and insurance coverage can have a direct impact on its financial results and, by extension, on returns for US shareholders. For example, discussions around Medicare reforms and inflation?linked rebates are closely tracked because they may affect AbbVie’s ability to maintain pricing on key products over time. Retail investors in the United States often watch these policy debates as part of a broader assessment of risks and opportunities in the healthcare sector.

Another consideration for US investors is AbbVie’s role as a dividend payer. Historically, the company has returned a substantial portion of cash to shareholders through regular dividends, using cash flows generated by its portfolio of established therapies. While future dividend decisions depend on factors such as earnings, cash needs and the broader economic environment, AbbVie’s existing track record is one reason income?focused investors follow the stock. At the same time, the capital requirements for research, acquisitions and debt servicing mean that capital allocation remains a central topic during investor presentations and quarterly calls.

Conclusion

AbbVie is navigating a complex transition as its long?time flagship drug Humira faces mounting biosimilar competition while newer therapies like Skyrizi and Rinvoq assume a more prominent role in the company’s growth profile. The most recent quarterly results underscore both the challenges of managing patent expirations and the potential of a diversified portfolio spanning immunology, oncology, neuroscience and aesthetics. For US investors, AbbVie’s exposure to domestic healthcare policy, its position within major equity indices and its history of shareholder returns make it a closely watched stock in the biopharma space. How effectively the company executes on its pipeline, manages pricing pressure and integrates its broad range of assets will likely remain central themes for the market in the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.